Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

about

Progress in the treatment of esophageal neuroendocrine carcinoma.Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.

P2860

Q39400425-3EBFCA9E-1C35-4F50-9492-02CE7A3D9D14 Q55263815-05EE07C7-89A6-43FF-B1F2-8B4910FDF41B

P2860

Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

Item

http://www.wikidata.org/entity/Q38769465

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Baseline chromogranin A and it ...... creatic neuroendocrine tumors.

@en

type

Item

label

Baseline chromogranin A and it ...... creatic neuroendocrine tumors.

@en

prefLabel

Baseline chromogranin A and it ...... creatic neuroendocrine tumors.

@en

P1476

Baseline chromogranin A and it ...... ncreatic neuroendocrine tumors

@en

P2093

Agnieszka Kolasińska-Ćwikła

http://www.w3.org/2001/XMLSchema#string

Anna Lewczuk

http://www.w3.org/2001/XMLSchema#string

Violetta Sulżyc-Bielicka

http://www.w3.org/2001/XMLSchema#string

Wojciech Rogowski

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.

The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties.

Circulating markers for endocrine tumours of the gastroenteropancreatic tract.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Chromogranin-A: a multifaceted cardiovascular role in health and disease.

P304

1069-1079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0455

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jaroslaw Cwikla

Ewa Wachuła

Ewa Izycka-Swieszewska

P577

2017-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28095720

http://www.w3.org/2001/XMLSchema#string

Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

about

P2860

P2860

Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698